Arrowhead Pharmaceuticals... (ARWR)
Arrowhead Pharmaceuticals Statistics
Share Statistics
Arrowhead Pharmaceuticals has 137.32M shares outstanding. The number of shares has increased by 10.56% in one year.
| Shares Outstanding | 137.32M |
| Shares Change (YoY) | 10.56% |
| Shares Change (QoQ) | 10.35% |
| Owned by Institutions (%) | 79.93% |
| Shares Floating | 114.31M |
| Failed to Deliver (FTD) Shares | 55 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 12.53M, so 9.94% of the outstanding shares have been sold short.
| Short Interest | 12.53M |
| Short % of Shares Out | 9.94% |
| Short % of Float | 13.19% |
| Short Ratio (days to cover) | 5.34 |
Valuation Ratios
The PE ratio is -3.87 and the forward PE ratio is -3.8. Arrowhead Pharmaceuticals's PEG ratio is -0.02.
| PE Ratio | -3.87 |
| Forward PE | -3.8 |
| PS Ratio | 653.4 |
| Forward PS | 2.7 |
| PB Ratio | 12.51 |
| P/FCF Ratio | -3.84 |
| PEG Ratio | -0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Arrowhead Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.74, with a Debt / Equity ratio of 2.75.
| Current Ratio | 6.74 |
| Quick Ratio | 6.74 |
| Debt / Equity | 2.75 |
| Debt / EBITDA | -0.91 |
| Debt / FCF | -0.84 |
| Interest Coverage | -18.58 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $5.83K |
| Profits Per Employee | $-984.39K |
| Employee Count | 609 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.77M |
| Effective Tax Rate | 0.45% |
Stock Price Statistics
The stock price has increased by -41.73% in the last 52 weeks. The beta is 1, so Arrowhead Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1 |
| 52-Week Price Change | -41.73% |
| 50-Day Moving Average | 14.59 |
| 200-Day Moving Average | 19.88 |
| Relative Strength Index (RSI) | 55.92 |
| Average Volume (20 Days) | 1.79M |
Income Statement
In the last 12 months, Arrowhead Pharmaceuticals had revenue of 3.55M and earned -599.49M in profits. Earnings per share was -5.
| Revenue | 3.55M |
| Gross Profit | 3.55M |
| Operating Income | -601.08M |
| Net Income | -599.49M |
| EBITDA | -561.51M |
| EBIT | -580.11M |
| Earnings Per Share (EPS) | -5 |
Balance Sheet
The company has 102.69M in cash and 510.55M in debt, giving a net cash position of -407.87M.
| Cash & Cash Equivalents | 102.69M |
| Total Debt | 510.55M |
| Net Cash | -407.87M |
| Retained Earnings | -1.63B |
| Total Assets | 1.01B |
| Working Capital | 476.78M |
Cash Flow
In the last 12 months, operating cash flow was -462.85M and capital expenditures -141.47M, giving a free cash flow of -604.32M.
| Operating Cash Flow | -462.85M |
| Capital Expenditures | -141.47M |
| Free Cash Flow | -604.32M |
| FCF Per Share | -5.05 |
Margins
Gross margin is 100%, with operating and profit margins of -16927.06% and -16882.37%.
| Gross Margin | 100% |
| Operating Margin | -16927.06% |
| Pretax Margin | -17247.54% |
| Profit Margin | -16882.37% |
| EBITDA Margin | -15812.81% |
| EBIT Margin | -16927.06% |
| FCF Margin | -17018.3% |
Dividends & Yields
ARWR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ARWR is $34.5, which is 145.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $34.5 |
| Price Target Difference | 145.4% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Stock Splits
The last stock split was on Nov 17, 2011. It was a backward split with a ratio of 1:10.
| Last Split Date | Nov 17, 2011 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -2.71 |
| Piotroski F-Score | 3 |